Sign in4 stories
A new filing shows AIM issued 1,749,434 shares to Streeterville Capital in September 2026, adding to two earlier rounds of note-to-equity exchanges disclosed the same month.
SEC filing (3)
In an August 11, 2026 8-K, AIM ImmunoTech furnished an article by CEO Thomas K. Equels arguing broad-spectrum antivirals like Ampligen should be evaluated before future outbreaks emerge.
SEC filing
AIM says it finished enrollment and dosing in its Phase 2 pancreatic cancer study and expects survival data in 2027, while cash rose to $9.9 million.
SEC filing
AIM ImmunoTech will pay Sterling Pharma Solutions about $1.5 million for Ampligen precursor materials while terminating its at-the-market equity agreement with Maxim Group.
SEC filing (2)